Table 2 Clonogenic survival between cell lines and treatment types at different concentrations
Concentration (nM) | Mean survival ± S.D. (%) | |||||||
|---|---|---|---|---|---|---|---|---|
PANC-1 | AsPC-1 | |||||||
[177Lu]Lu-DOTA-C595 | Lu-177 | DOTA-C595 | C595 | [177Lu]Lu-DOTA-C595 | Lu-177 | DOTA-C595 | C595 | |
100 | 47.2 ± 9.3 | 40.3 ± 9.5 | 28.4 ± 3.7 | 10.7 ± 4.1 | 15.6 ± 3.3 | 28.1 ± 4.4 | 36.4 ± 3.4 | 64.4 ± 3.6 |
250 | 11.0 ± 3.7 | – | – | – | 11.1 ± 1.3 | – | – | – |
500 | 12.5 ± 6.4 | 14.4 ± 1.5 | 10.2 ± 8.8 | 8.90 ± 5.1 | 28.9 ± 1.7 | 9.90 ± 1.1 | 13.3 ± 12.1 | 56.2 ± 6.5 |
750 | 12.5 ± 4.1 | 8.05 ± 1.9 | 17.8 ± 4.6 | 15.0 ± 3.7 | 29.3 ± 3.9 | 13.5 ± 2.5 | 47.8 ± 2.3 | 74.6 ± 9.3 |
1000 | 11.7 ± 4.2 | 7.20 ± 4.8 | 27.1 ± 13.2 | 27.7 ± 5.4 | 24.4 ± 2.7 | 1.74 ± 0.5 | 24.1 ± 4.3 | 69.8 ± 5.8 |
2000 | 1.98 ± 0.98 | – | – | – | 3.85 ± 0.78 | – | – | – |
3000 | 0.74 ± 1.0 | – | 45.8 ± 24.8 | 19.6 ± 6.6 | 0.72 ± 0.74 | – | 43.5 ± 14.8 | 50.6 ± 1.8 |